Previous Columns

CRISPR Therapeutics' one-time liver edit kept cholesterol and triglycerides down a year after infusion, proving durability for the first time, though the company's own protocol tracks these patients for years past this readout.

Wall Street revalued Moderna by $45 billion on a topline label alone, and the number that would actually justify that move stays sealed until October.

Deep Robotics timed a single-take video of a robot climbing stairs to the week China's humanoid IPO mania peaked, because four units sold in two years can't do that job.

IBM's open Quantum Advantage Tracker matters less as proof quantum computers won and more as published circuits that more than 30 outside teams have now tried, and failed, to break.

Tether, the company behind the world's largest stablecoin, has quietly become a serious funder of brain implants for paralysis, and its reserve-driven balance sheet may outlast biotech's usual venture cycle.

Starship's 13th flight proved the ship survives and the payload works in the same mission, which means the real bottleneck now sits in the satellite factory, not the rocket.

Neuracle's brain implant has treated 32 patients and earned zero revenue, yet Beijing built a reimbursement code, and Neuracle filed a $345m IPO, faster than the clinical evidence justifies.

This week paired a bidirectional touch-restoring brain implant with China's first commercial brain-computer interface, and the commercial one, despite the bigger headline, is solving the easier engineering problem.